Immunotherapy in Non-Small Cell Lung Cancer: Shifting Prognostic Paradigms

Megan B Barnet; Wendy A Cooper; Michael J Boyer; Steven Kao

doi:10.3390/jcm7060151

Immunotherapy in Non-Small Cell Lung Cancer: Shifting Prognostic Paradigms

J Clin Med. 2018 Jun 14;7(6):151. doi: 10.3390/jcm7060151.

Authors

Megan B Barnet^{1

2

3}, Wendy A Cooper^{4

5

6}, Michael J Boyer^{7

8}, Steven Kao^{9

10}

Affiliations

¹ The Garvan Institute of Medical Research, Darlinghurst, NSW 2010, Australia. m.barnet@garvan.org.au.
² Graduate Research School, University of New South Wales, Sydney, NSW 2052, Australia. m.barnet@garvan.org.au.
³ Sydney Medical School, The University of Sydney, Camperdown, NSW 2006, Australia. m.barnet@garvan.org.au.
⁴ Sydney Medical School, The University of Sydney, Camperdown, NSW 2006, Australia. wendy.cooper@health.nsw.gov.au.
⁵ Royal Prince Alfred Hospital, Camperdown, NSW 2006, Australia. wendy.cooper@health.nsw.gov.au.
⁶ School of Medicine, Western Sydney University, Penrith, NSW 2751, Australia. wendy.cooper@health.nsw.gov.au.
⁷ Sydney Medical School, The University of Sydney, Camperdown, NSW 2006, Australia. michael.boyer@lh.org.au.
⁸ The Chris O'Brien Lifehouse, Camperdown, NSW 2006, Australia. michael.boyer@lh.org.au.
⁹ Sydney Medical School, The University of Sydney, Camperdown, NSW 2006, Australia. steven.kao@lh.org.au.
¹⁰ The Chris O'Brien Lifehouse, Camperdown, NSW 2006, Australia. steven.kao@lh.org.au.

Abstract

Immune checkpoint inhibitors have shown efficacy in the treatment of non-small cell lung cancer (NSCLC) in the adjuvant, first- and subsequent-line settings. In metastatic disease, they provide hope of durable response where “best-case” scenario has long been inadequate. This progress has highlighted the immunogenic nature of NSCLC and invigorated research into immunotherapy in the field. In this review we consider the foundations of immunotherapy in NSCLC, canvass the current research and summarise the evidence guiding clinical practice.

Keywords: checkpoint inhibitors; immunotherapy; non-small cell lung cancer.

Publication types

Review